Massive Bio vs Paradigm Health (2026)
The two strongest evidenced trial matching companies, and they differ on where the matching happens. Paradigm deploys inside the provider record system, reasons over full text notes with language models rather than structured prefilters, and pairs the software with recruitment staff across a network spanning dozens of states and well over a hundred provider organisations. Massive Bio matches without requiring an integration at all, covering oncology and haematology against a very large active trial list, with every match audited by certified oncology case managers and rare peer reviewed prospective evidence behind it. For a health system building trial capacity into routine oncology care, Paradigm is the deeper answer and the longer implementation. For a site or a patient who needs matching to work this month, Massive Bio removes the integration entirely, which is usually what kills these projects.
- It matches without needing an integration at all, which removes the longest pole in most trial matching deployments and lets a site or a patient start now rather than after an IT project.
- Rare peer reviewed prospective evidence for a matching product, published in an oncology real world data journal, against a category where most matching claims are retrospective and vendor run.
- Every generated match is audited by certified oncology case managers before it is used, so the human is structurally in the path rather than nominally responsible for it.
- The eligibility reasoning is done by language models over full text notes rather than structured prefilters alone, and the company published a direct comparison making that case rather than asserting it.
- Network reach is specific and verifiable, spanning dozens of states and well over a hundred provider organisations including designated cancer centres, which is the constraint that actually determines whether a patient finds a trial.
- It deploys inside the provider record system and pairs the software with recruitment staff, so the site is not left to convert matches into enrolments on its own.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Massive Bio and Paradigm Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Massive Bio | Paradigm Health |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2015 | 2021 |
| Headquarters | Boca Raton, Florida | Boston, Massachusetts, United States |
| Website | massivebio.com | paradigmhealth.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Massive Bio its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Paradigm Health, Massive Bio grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Paradigm Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Massive Bio, Paradigm Health grades higher on EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Massive Bio or Paradigm Health?
On the axes where the AI Health Index separates them, Massive Bio grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture, and Paradigm Health grades higher on EHR and Interoperability Depth. Massive Bio leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Massive Bio and Paradigm Health differ most?
The widest separation the AI Health Index records between Massive Bio and Paradigm Health is on Model Supply Chain Disclosure, where Massive Bio grades B and Paradigm Health grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Massive Bio and Paradigm Health grade the same?
The AI Health Index grades Massive Bio and Paradigm Health the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Trial matching carries a documentation bias that neither vendor fully addresses: a patient whose record is thin, whose care is fragmented across systems, or whose notes are written in less structured language will match less often regardless of clinical eligibility, and that population overlaps with the one trials already under enrol. Neither vendor publishes a security attestation or trust centre, and neither publishes pricing.
Paradigm's business associate status is structurally required and nothing is published on it. Massive Bio's model documentation and bias evaluation were not located, and its patient facing route raises a separate question about who is paying for a match a patient found for themselves.